Metamark is leading a shift in urological cancer care to enable patients and their physicians to make informed tretment decisions that lead to better quality of life and lower cost of care.

LEARN MORE

Press Release

Study Demonstrates Cost-effectiveness of New Assay to Inform Treatment Decisions Compared to Guidelines-based Care

Data published in The Oncologist support use of ProMark® as a likely cost-effective addition to current guidelines for management of Gleason 3+3 and 3+4 early-stage prostate cancer.

read article
Press Release

Metamark Announces Publication of Clinical Validation Study for the ProMark™ Prostate Cancer Prognostic Test

Metamark announced today that results of its clinical validation study for the ProMark™ prostate cancer test were published online in Clinical Cancer Research.

read article
Displaying results 5-6 (of 13)
 |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|